All Stories

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh phase 3 readout.

May 28, 2025 - 14:50
 0
GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win
GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh phase 3 readout.
Read More

Tags:

Previous Article

Merck KGaA shares phase 3 rare tumor data ahead of showdown with Daiichi and Ono

Next Article

Fierce Biotech Layoff Tracker 2025: iTeos winds down; Boundless lets go of 33% o...

Related Posts

Regeneron’s $256M bid wins 23andMe bankruptcy auction

Regeneron’s $256M bid wins 23andMe bankruptcy auction

May 19, 2025  0

Eli Lilly lands next-gen pain asset in SiteOne Therapeutics acquisition worth up to $1B

Eli Lilly lands next-gen pain asset in SiteOne Therapeu...

May 27, 2025  0

Prothena reburies drug after second swing at rare disease misses, plans ‘substantial’ layoffs

Prothena reburies drug after second swing at rare disea...

May 27, 2025  0